ULTRAGENYX PHARMACEUTICAL INC. (RARE) Operating cash flow 2016–2025
ULTRAGENYX PHARMACEUTICAL INC. (RARE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$466.0MFY2025 · since FY2016: -$161.0M → -$466.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$466.0M | -12.6% |
| FY2024 | -$414.0M | +12.8% |
| FY2023 | -$475.0M | -24.8% |
| FY2022 | -$380.5M | -12.3% |
| FY2021 | -$338.7M | -156.2% |
| FY2020 | -$132.2M | +61.7% |
| FY2019 | -$345.4M | -18.9% |
| FY2018 | -$290.6M | -14.5% |
| FY2017 | -$253.8M | -57.7% |
| FY2016 | -$161.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RARE financial trends
RARE RevenueRARE Net incomeRARE Net marginRARE Gross profitRARE Gross marginRARE Operating incomeRARE Operating marginRARE Free cash flowRARE Capital expendituresRARE Return on equityRARE Stock buybacksRARE Dividends paidRARE Total assetsRARE Total liabilitiesRARE Shareholders’ equityRARE overview →